Nuclear Receptor-Mediated Regulation of Phase II Conjugating Enzymes

Nuclear Receptors in Drug Metabolism

Volumn , Issue , 2008, Pages 61-110

  Barbier, Oliver ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

CAR and PXR xenosensors; Phase I nuclear receptor mediated regulation; PPARs and PHASE II XMEs regulation

Indexed keywords

EID: 74549217451     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470409107.ch3     Document Type: Chapter

References (257)

1. Iyanagi, T. (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int. Rev. Cytol. 260, 35-112.
2. Dutton, G. J. (1980) Glucuronidation of Drugs and Other Compounds. CRC Press, Boca Raton, FL.
3. Zamek-Gliszczynski,M. J., Hoffmaster, K. A., Nezasa, K., Tallman,M. N., and Brouwer, K. L. (2006) Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci. 27, 447-486.
4. Aleksunes, L. M. andManautou, J. E. (2007) Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol. Pathol. 35, 459-473.
5. Evans, W. E. and Relling, M. V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491.
6. Bélanger, A., Pelletier, G., Labrie, F., Barbier, O., and Chouinard, S. (2003) Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol. Metab. 14, 473-479.
7. Wells, P. G., Mackenzie, P. I., Chowdhury, J. R., Guillemette, C., Gregory, P. A., Ishii, Y., Hansen, A. J., Kessler, F. K., Kim, P. M., Chowdhury, N. R., et al. (2004) Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 32, 281-290.
8. Shipkova, M. and Wieland, E. (2005) Glucuronidation in therapeutic drug monitoring. Clin. Chim. Acta. 358, 2-23.
9. Sallustio, B. C., Sabordo, L., Evans, A. M., and Nation, R. L. (2000) Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr. Drug Metab. 1, 163-180.
10. Mackenzie, P. I., Bock, K. W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., Miners, J. O., Owens, I. S., and Nebert, D.W. (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenetics Genomics 15, 677-685.
11. Girard, H., Lévesque, É., Bellemare, J., Journault, K., Caillier, B., and Guillemette, C. (2007) Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenetics Genomics 17, 1077-1089.
12. Lévesque, É., Girard, H., Journault, K., Lépine, J., and Guillemette, C. (2007) Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a newsplicing event at the UGT1A locus. Hepatology 45, 128-138.
13. Tukey, R. H. and Strassburg, C. P. (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616.
14. Miners, J. O., Knights, K. M., Houston, J. B., and Mackenzie, P. I. (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. 71, 1531-1539.
15. Miners, J. O., Smith, P. A., Sorich, M. J., McKinnon, R. A., and Mackenzie, P. I. (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu. Rev. Pharmacol. Toxicol. 44, 1-25.
16. Bosma, P. J., Seppen, J., Goldhoorn, B., Bakker, C., Oude Elferink, R. P., Chowdhury, J. R., Chowdhury, N. R., and Jansen, P. L. (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J. Biol. Chem. 269, 17960-17964.
17. Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N., Jansen, P. L., Oude Elferink, R. P., et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175.
18. Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., and Mackenzie, P. I. (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J. Pharmacol. Exp. Ther. 299, 998-1006.
19. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., and Ball, S. E. (2004) Drug-drug interactions for UDPglucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32, 1201-1208.
20. Coffman, B. L., Rios, G. R., King, C. D., and Tephly, T. R. (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25, 1-4.
21. Barbier, O., Turgeon, D., Girard, C., Green, M. D., Tephly, T. R., Hum, D. W., and Bélanger, A. (2000) 3'-Azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos. 28, 497-502.
22. Crayford, J. V. and Hutson, D. H. (1980) Comparative metabolism of phenobarbitone in the rat (CFE) and mouse (CF1). Food Cosmet. Toxicol. 18, 503-509.
23. Buhl, A. E., Waldon, D. J., Baker, C. A., and Johnson, G. A. (1990) Minoxidil sulfate is the active metabolite that stimulates hair follicles. J. Invest. Dermatol. 95, 553-557.
24. Glatt, H., Davis, W., Meinl, W., Hermersdorfer, H., Venitt, S., and Phillips, D. H. (1998) Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 19, 1709-1713.
25. Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627-635.
26. Nowell, S. and Falany, C. N. (2006) Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 25, 1673-1678.
27. Huttner, W. B. (1988) Tyrosine sulfation and the secretory pathway. Annu. Rev. Physiol. 50, 363-376.
28. Liyou, N. E., Buller, K. M., Tresillian, M. J., Elvin, C. M., Scott, H. L., Dodd, P. R., Tannenberg, A. E., and McManus, M. E. (2003) Localization of a brain sulfotransferase, SULT4A1, in the human and rat brain: an immunohistochemical study. J. Histochem. Cytochem. 51, 1655-1664.
29. Glatt, H. (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem. Biol. Interact. 129, 141-170.
30. Otterness, D. M., Wieben, E. D., Wood, T. C., Watson, W. G., Madden, B. J., Mc-Cormick, D. J., and Weinshilboum, R. M. (1992) Human liver dehydroepiandrosterone sulfotransferase: molecular cloning and expression of cDNA. Mol. Pharmacol. 41, 865-872.
31. Her, C., Wood, T. C., Eichler, E. E., Mohrenweiser, H. W., Ramagli, L. S., Siciliano, M. J., and Weinshilboum, R. M. (1998) Human hydroxysteroid sulfotransferase SULT2B1, two enzymes encoded by a single chromosome 19 gene. Genomics 53, 284-295.
32. Strott, C. A. (2002) Sulfonation and molecular action. Endocr. Rev. 23, 703-732.
33. Gamage, N., Barnett, A., Hempel, N., Duggleby, R. G.,Windmill, K. F., Martin, J. L., and McManus,M. E. (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 90, 5-22.
34. Radominska,A., Comer, K. A., Zimniak, P., Falany, J., Iscan,M., and Falany, C. N. (1990) Human liver steroid sulphotransferase sulphates bile acids. Biochem. J. 272, 597-604.
35. Nagata, K., Ozawa, S., Miyata, M., Shimada, M., Gong, D. W., Yamazoe, Y., and Kato, R. (1993) Isolation and expression of a cDNA encoding a male-specific rat sulfotransferase that catalyzes activation of N-hydroxy-2-acetylaminofluorene. J. Biol. Chem. 268, 24720-24725.
36. Mulder, G. J. and Scholtens, E. (1978) The availability of inorganic sulphate in blood for sulphate conjugation of drugs in rat liver in vivo. (35S)Sulphate incorporation into harmol sulphate. Biochem. J. 172, 247-251.
37. Hjelle, J. J., Hazelton, G. A., and Klaassen, C. D. (1985) Acetaminophen decreases adenosine 3'-phosphate 5'-phosphosulfate and uridine diphosphoglucuronic acid in rat liver. Drug Metab. Dispos. 13, 35-41.
38. Kim, H. J., Rozman, P., Madhu, C., and Klaassen, C. D. (1992) Homeostasis of sulfate and 3'-phosphoadenosine 5'-phosphosulfate in rats after acetaminophen administration. J. Pharmacol. Exp. Ther. 261, 1015-1021.
39. Pang, K. S., Schwab, A. J., Goresky, C. A., and Chiba, M. (1994) Transport, binding, and metabolism of sulfate conjugates in the liver. Chem. Biol. Interact. 92, 179-207.
40. Pang, K. S., Koster, H., Halsema, I. C., Scholtens, E., and Mulder, G. J. (1981) Aberrant pharmacokinetics of harmol in the perfused rat liver preparation: sulfate and glucuronide conjugations. J. Pharmacol. Exp. Ther. 219, 134-140.
41. Pang, K. S., Koster, H., Halsema, I. C., Scholtens, E., Mulder, G. J., and Stillwell, R. N. (1983) Normal and retrograde perfusion to probe the zonal distribution of sulfation and glucuronidation activities of harmol in the perfused rat liver preparation. J. Pharmacol. Exp. Ther. 224, 647-653.
42. Morris, M. E., Yuen, V., and Pang, K. S. (1988) Competing pathways in drugmetabolism. II. An identical, anterior enzymic distribution for 2- and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver. J. Pharmacokinet. Biopharm. 16, 633-656.
43. Ratna, S., Chiba, M., Bandyopadhyay, L., and Pang, K. S. (1993) Futile cycling between 4-methylumbelliferone and its conjugates in perfused rat liver. Hepatology 17, 838-853.
44. Smith, P. C., McDonagh, A. F., and Benet, L. Z. (1990) Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. J. Pharmacol. Exp. Ther. 252, 218-224.
45. Liu, J. H. and Smith, P. C. (2006) Predicting the pharmacokinetics of acyl glucuronides and their parent compounds in disease states. Curr. Drug Metab. 7, 147-163.
46. Roberts, M. S., Magnusson, B. M., Burczynski, F. J., and Weiss, M. (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41, 751-790.
47. Shipkova,M., Armstrong, V.W., Oellerich,M., andWieland, E. (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25, 1-16.
48. Duanmu, Z., Dunbar, J., Falany, C. N., and Runge-Morris, M. (2000) Induction of rat hepatic aryl sulfotransferase (SULT1A1) gene expression by triamcinolone acetonide: impact on minoxidil-mediated hypotension. Toxicol. Appl. Pharmacol. 164, 312-320.
49. Duvoix, A., Schnekenburger, M., Delhalle, S., Blasius, R., Borde-Chiche, P., Morceau, F., Dicato, M., and Diederich, M. (2004) Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett. 216, 207-219.
50. Kim, S. K., Abdelmegeed, M. A., and Novak, R. F. (2006) Identification of the insulin signaling cascade in the regulation of alpha-class glutathione S-transferase expression in primary cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 316, 1255-1261.
51. Morgenstern, R., Lundqvist, G., Andersson, G., Balk, L., and DePierre, J.W. (1984) The distribution of microsomal glutathione transferase among different organelles, different organs, and different organisms. Biochem. Pharmacol. 33, 3609-3614.
52. DeRidder, B. P. and Goldsbrough, P. B. (2006) Organ-specific expression of glutathione S-transferases and the efficacy of herbicide safeners in Arabidopsis. Plant Physiol. 140, 167-175.
53. Edwards, R., Dixon, D. P., and Walbot, V. (2000) Plant glutathione S-transferases: enzymes with multiple functions in sickness and in health. Trends Plant. Sci. 5, 193-198.
54. Haimeur, A., Conseil, G., Deeley, R. G., and Cole, S. P. (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5, 21-53.
55. Sheehan, D., Meade, G., Foley, V. M., and Dowd, C. A. (2001) Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem. J. 360, 1-16.
56. Hayes, J. D., Flanagan, J. U., and Jowsey, I. R. (2005) Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45, 51-88.
57. Nishinaka, T., Ichijo,Y., Ito, M.,Kimura, M., Katsuyama,M., Iwata, K.,Miura, T., Terada, T., and Yabe-Nishimura, C. (2007) Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol. Lett. 170, 238-247.
58. Pool-Zobel, B., Veeriah, S., and Bohmer, F. D. (2005) Modulation of xenobiotic metabolising enzymes by anticarcinogens-focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutat. Res. 591, 74-92.
59. Mannervik, B., Alin, P., Guthenberg, C., Jensson, H., Tahir, M. K., Warholm, M., and Jornvall, H. (1985) Identification of three classes of cytosolic glutathione transferase common to severalmammalian species: correlation between structural data and enzymatic properties. Proc. Natl Acad. Sci. USA 82, 7202-7206.
60. Sun, Q., Komura, S., Ohishi, N., and Yagi, K. (1996) Alpha-class isozymes of glutathione S-transferase in rat liver cytosol possess glutathione peroxidase activity toward phospholipid hydroperoxide. Biochem. Mol. Biol. Int. 39, 343-352.
61. Yusof, Y. A., Yan, K. L., and Hussain, S. N. (2003) Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease. Anal. Quant. Cytol. Histol. 25, 332-338.
62. Park, E. Y., Cho, I. J., and Kim, S. G. (2004) Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res. 64, 3701-3713.
63. Salinas, A. E. andWong, M. G. (1999) Glutathione S-transferases-a review. Curr. Med. Chem. 6, 279-309.
64. Vargo, M. A. and Colman, R. F. (2001) Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta-iodoacetoxy-estradiol-3-sulfate. J. Biol. Chem. 276, 2031- 2036.
65. Sim, E., Westwood, I., and Fullam, E. (2007) Arylamine N-acetyltransferases. Expert Opin. Drug Metab. Toxicol. 3, 169-184.
66. Weinshilboum, R. M. (2006) Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cell Mol. Neurobiol. 26, 539-561.
67. Shimada, T. (2006) Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab. Pharmacokinet. 21, 257-276.
68. Chiamvimonvat, N., Ho, C. M., Tsai, H. J., and Hammock, B. D. (2007) The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 50, 225-237.
69. Selye, H. (1972) Prevention by catatoxic steroids of lithocholic acid-induced biliary concrements in the rat. Proc. Soc. Exp. Biol. Med. 141, 555-558.
70. Timsit, Y. E. and Negishi, M. (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72, 231-246.
71. Stanley, L. A., Horsburgh, B. C., Ross, J., Scheer, N., and Wolf, C. R. (2006) PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab. Rev. 38, 515-597.
72. Ekins, S.,Mirny, L., and Schuetz, E. G. (2002) A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm. Res. 19, 1788-1800.
73. Moore, L. B., Maglich, J. M., McKee, D. D., Wisely, B., Willson, T. M., Kliewer, S. A., Lambert, M. H., and Moore, J. T. (2002) Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol. 16, 977-986.
74. Tzameli, I. and Moore, D. D. (2001) Role reversal: new insights from new ligands for the xenobiotic receptor CAR. Trends Endocrinol. Metab. 12, 7-10.
75. Pascussi, J.M., Gerbal-Chaloin, S., Duret, C., Daujat-Chavanieu, M., Vilarem, M. J., and Maurel, P. (2008) The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu. Rev. Pharmacol. Toxicol. 48, 1-32.
76. Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275, 15122-15127.
77. Lehmann, J. M.,McKee, D. D.,Watson, M. A.,Willson, T. M.,Moore, J. T., and Kliewer, S. A. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023.
78. Moore, J. T. and Kliewer, S. A. (2000) Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153, 1-10.
79. Staudinger, J. L., Goodwin, B., Jones, S. A., Hawkins-Brown, D., MacKenzie, K. I., LaTour, A., Liu, Y., Klaassen, C. D., Brown, K. K., Reinhard, J., et al. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 98, 3369-3374.
80. Kretschmer, X. C. and Baldwin, W. S. (2005) CAR and PXR: xenosensors of endocrine disrupters? Chem. Biol. Interact. 155, 111-128.
81. Forman, B. M., Tzameli, I., Choi, H. S., Chen, J., Simha, D., Seol,W., Evans, R. M., and Moore, D. D. (1998) Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395, 612-615.
82. Lamba, J. K., Lamba, V., Yasuda, K., Lin, Y. S., Assem, M., Thompson, E., Strom, S., and Schuetz, E. (2004) Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J. Pharmacol. Exp. Ther. 311, 811-821.
83. Gardner-Stephen, D., Heydel, J. M., Goyal, A., Lu, Y., Xie,W., Lindblom, T.,Mackenzie, P., and Radominska-Pandya, A. (2004) Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab. Dispos. 32, 340-347.
84. Westerink,W. M. and Schoonen,W. G. (2007) Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21, 1592-1602.
85. Schuetz, E. G., Hazelton, G. A., Hall, J., Watkins, P. B., Klaassen, C. D., and Guzelian, P. S. (1986) Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J. Biol. Chem. 261, 8270-8275.
86. Chen, C., Staudinger, J. L., and Klaassen, C. D. (2003) Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltransferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab. Dispos. 31, 908-915.
87. Xie, W., Yeuh, M. F., Radominska-Pandya, A., Saini, S. P., Negishi, Y., Bottroff, B. S., Cabrera, G. Y., Tukey, R. H., and Evans, R. M. (2003) Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc. Natl Acad. Sci. USA 100, 4150-4155.
88. Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., and Evans, R. M. (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406, 435-439.
89. Xie, W. and Evans, R. M. (2002) Pharmaceutical use of mouse models humanized for the xenobiotic receptor. Drug Discov. Today 7, 509-515.
90. Xie, W., Barwick, J. L., Simon, C. M., Pierce, A. M., Safe, S., Blumberg, B., Guzelian, P. S., and Evans, R. M. (2000) Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 14, 3014-3023.
91. Zhou, J., Zhang, J., and Xie, W. (2005) Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr. Drug Metab. 6, 289-298.
92. Chen, S., Beaton, D., Nguyen, N., Senekeo-Effenberger, K., Brace-Sinnokrak, E., Argikar, U., Remmel, R. P., Trottier, J., Barbier, O., Ritter, J. K., et al. (2005) Tissuespecific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J. Biol. Chem. 280, 37547-37557.
93. Sonoda, J., Xie, W., Rosenfeld, J. M., Barwick, J. L., Guzelian, P. S., and Evans, R. M. (2002) Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl Acad. Sci. USA 99, 13801-13806.
94. Alnouti, Y. and Klaassen, C. D. (2008) Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. J. Pharmacol. Exp. Ther. 324 (2), 612-621.
95. DePierre, J. W., Seidegard, J., Morgenstern, R., Balk, L., Meijer, J., Astrom, A., Norelius, I., and Ernster, L. (1984) Induction of cytosolic glutathione transferase and microsomal epoxide hydrolase activities in extrahepatic organs of the rat by phenobarbital, 3-methylcholanthrene and trans-stilbene oxide. Xenobiotica 14, 295-301.
96. Rae, J. M., Johnson, M. D., Lippman, M. E., and Flockhart, D. A. (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299, 849-857.
97. Shibayama, Y., Ikeda, R., Motoya, T., and Yamada, K. (2004) St. John's wort (hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study. Food Chem. Toxicol. 42, 995-1002.
98. Gong, H., Singh, S. V., Singh, S. P., Mu, Y., Lee, J. H., Saini, S. P., Toma, D., Ren, S., Kagan, V. E., Day, B. W., et al. (2006) Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol. Endocrinol. 20, 279-290.
99. Saini, S. P., Mu, Y., Gong, H., Toma, D., Uppal, H., Ren, S., Li, S., Poloyac, S. M., and Xie, W. (2005) Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. Hepatology 41, 497-505.
100. Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., and Moore, D. D. (2003) Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl Acad. Sci. USA 100, 4156-4161.
101. Tong, Z., Li, H., Goljer, I., McConnell, O., and Chandrasekaran, A. (2007) In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases. Drug Metab. Dispos. 35, 2203-2210.
102. Eiris-Punal, J., Del Rio-Garma, M., Del Rio-Garma, M. C., Lojo-Rocamonde, S., Novo-Rodriguez, I., and Castro-Gago, M. (1999) Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 40, 1761-1766.
103. Klaassen, C. D. and Hood, A. M. (2001) Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. Toxicol. Pathol. 29, 34-40.
104. Maglich, J. M., Watson, J., McMillen, P. J., Goodwin, B., Willson, T. M., and Moore, J. T. (2004) The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J. Biol. Chem. 279, 19832-19838.
105. Qatanani, M., Zhang, J., and Moore, D. D. (2005) Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 146, 995-1002.
106. Xie, W., Radominska-Pandya, A., Shi, Y., Simon, C. M., Nelson, M. C., Ong, E. S., Waxman, D. J., and Evans, R. M. (2001) An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl Acad. Sci. USA 98, 3375-3380.
107. Goodwin, B., Gauthier, K. C., Umetani, M., Watson, M. A., Lochansky, M. I., Collins, J. L., Leitersdorf, E., Mangelsdorf, D. J., Kliewer, S. A., and Repa, J. J. (2003) Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl Acad. Sci. USA 100, 223-228.
108. Trottier, J.,Milkiewicz, P., Kaeding, J., Verreault, M., and Barbier, O. (2006) Coordinate regulation of hepatic bile acid oxidation and conjugation by nuclear receptors. Mol. Pharm. 3, 212-222.
109. Wietholtz, H., Marschall, H. U., Sjovall, J., and Matern, S. (1996) Stimulation of bile acid 6 alpha-hydroxylation by rifampin. J. Hepatol. 24, 713-718.
110. Khurana, S. and Singh, P. (2006) Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 26, 943-948.
111. Lépine, J., Bernard, O., Plante, M., Tetu, B., Pelletier, G., Labrie, F., Bélanger, A., and Guillemette, C. (2004) Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J. Clin. Endocrinol. Metab. 89, 5222-5232.
112. Falany, J. L., Macrina, N., and Falany, C. N. (2002) Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation. Breast Cancer Res. Treat. 74, 167-176.
113. Chen, J. and Raymond, K. (2006) Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann. Clin. Microbiol. Antimicrob. 5, 3.
114. Dlodlo, R. A., Fujiwara, P. I., and Enarson, D. A. (2005) Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Eur. Respir. J. 25, 751-757.
115. Davies, P.D. andYew,W.W. (2003) Recent developments in the treatment of tuberculosis. Expert Opin. Investig. Drugs 12, 1297-1312.
116. Gallicano, K. D., Sahai, J., Shukla, V. K., Seguin, I., Pakuts, A., Kwok, D., Foster, B. C., and Cameron, D.W. (1999) Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br. J. Clin. Pharmacol. 48, 168-179.
117. Ebert, U., Thong, N. Q., Oertel, R., and Kirch,W. (2000) Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol. 56, 299-304.
118. Fromm, M. F., Eckhardt, K., Li, S., Schanzle, G., Hofmann, U., Mikus, G., and Eichelbaum, M. (1997) Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 72, 261-267.
119. Lin, J. H. and Lu, A. Y. (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35, 361-390.
120. Echchgadda, I., Song, C. S., Oh, T., Ahmed, M., De La Cruz, I. J., and Chatterjee, B. (2007) The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase. Mol. Endocrinol. 21, 2099-2111.
121. Echchgadda, I., Song, C. S., Oh, T. S., Cho, S. H., Rivera, O. J., and Chatterjee, B. (2004) Gene regulation for the senescence marker protein DHEA-sulfotransferase by the xenobiotic-activated nuclear pregnane X receptor (PXR). Mech. Ageing Dev. 125, 733-745.
122. Echchgadda, I., Song, C. S., Roy, A. K., and Chatterjee, B. (2004) Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 65, 720-729.
123. Ferraris, A., D'Amato, G., Nobili, V., Torres, B., Marcellini, M., and Dallapiccola, B. (2006) Combined test for UGT1A1 -3279T->G and A(TA)nTAA polymorphisms best predicts Gilbert's syndrome in Italian pediatric patients. Genet. Test 10, 121-125.
124. Kitagawa, C., Ando, M., Ando, Y., Sekido, Y., Wakai, K., Imaizumi, K., Shimokata, K., and Hasegawa, Y. (2005) Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenetics Genomics 15, 35-41.
125. Pascussi, J. M., Drocourt, L., Fabre, J. M., Maurel, P., and Vilarem, M. J. (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol. 58, 361-372.
126. Huss, J. M. and Kasper, C. B. (1998) Nuclear receptor involvement in the regulation of rat cytochrome P450 3A23 expression. J. Biol. Chem. 273, 16155-16162.
127. Pascussi, J. M., Gerbal-Chaloin, S., Fabre, J. M., Maurel, P., and Vilarem, M. J. (2000) Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol. Pharmacol. 58, 1441-1450.
128. Sugatani, J., Yamakawa, K., Tonda, E., Nishitani, S., Yoshinari, K., Degawa, M., Abe, I., Noguchi,H., andMiwa, M. (2004) The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem. Pharmacol. 67, 989-1000.
129. Sugatani, J., Nishitani, S., Yamakawa, K., Yoshinari, K., Sueyoshi, T., Negishi, M., and Miwa, M. (2005) Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 67, 845-855.
130. Nebert, D. W., Jaiswal, A. K., Meyer, U. A., and Gonzalez, F. J. (1987) Human P-450 genes: evolution, regulation and possible role in carcinogenesis. Biochem. Soc. Trans. 15, 586-589.
131. Nebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., and Dalton, T. P. (2000) Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharmacol. 59, 65-85.
132. Kewley, R. J., Whitelaw, M. L., and Chapman-Smith, A. (2004) The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int. J. Biochem. Cell Biol. 36, 189-204.
133. Kazlauskas, A., Poellinger, L., and Pongratz, I. (2000) The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localization of the dioxin receptor. J. Biol. Chem. 275, 41317-41724.
134. Gu, Y. Z., Hogenesch, J. B., and Bradfield, C. A. (2000) The PAS superfamily: sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol. 40, 519-561.
135. Hankinson, O. (1995) The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 35, 307-340.
136. Whitlock, J. P., Jr. (1999) Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39, 103-125.
137. Yueh, M. F., Bonzo, J. A., and Tukey, R. H. (2005) The role of Ah receptor in induction of human UDP-glucuronosyltransferase 1A1. Methods Enzymol. 400, 75-91.
138. Birnbaum, L. S. and Tuomisto, J. (2000) Non-carcinogenic effects of TCDD in animals. Food Addit. Contam. 17, 275-288.
139. Ciolino, H. P., Daschner, P. J., and Yeh, G. C. (1999) Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 340 (Pt. 3), 715-722.
140. Uda, Y., Price, K. R., Williamson, G., and Rhodes, M. J. (1997) Induction of the anticarcinogenic marker enzyme, quinone reductase, in murine hepatoma cells in vitro by flavonoids. Cancer Lett. 120, 213-216.
141. Zhao, J. and Agarwal, R. (1999) Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 20, 2101-2108.
142. Moon, Y. J.,Wang, X., and Morris, M. E. (2006) Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro 20, 187-210.
143. Eisenbrand, G. and Tang,W. (1993) Food-borne heterocyclic amines. Chemistry, formation, occurrence and biological activities. A literature review. Toxicology 84, 1-82.
144. Lijinsky, W. and Shubik, P. (1964) Benzo(a)pyrene and other polynuclear hydrocarbons in charcoal-broiled meat. Science 145, 53-55.
145. Sugimura, T. (2000) Nutrition and dietary carcinogens. Carcinogenesis 21, 387-395.
146. Yueh, M. F., Huang, Y. H., Hiller, A., Chen, S., Nguyen, N., and Tukey, R. H. (2003) Involvement of the xenobiotic response element (XRE) in Ah receptormediated induction of human UDP-glucuronosyltransferase 1A1. J. Biol. Chem. 278, 15001-15006.
147. Sugatani, J., Sueyoshi, T., Negishi, M., and Miwa, M. (2005) Regulation of the human UGT1A1 gene by nuclear receptors constitutive active/androstane receptor, pregnane X receptor, and glucocorticoid receptor. Methods. Enzymol. 400, 92-104.
148. Bonzo, J. A., Belanger, A., and Tukey, R. H. (2007) The role of chrysin and the Ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice. Hepatology 45, 349-360.
149. Metz, R. P. and Ritter, J. K. (1998) Transcriptional activation of the UDPglucuronosyltransferase 1A7 gene in rat liver by aryl hydrocarbon receptor ligands and oltipraz. J. Biol. Chem. 273, 5607-5614.
150. Sohn, O. S., Surace, A., Fiala, E. S., Richie, J. P., Jr., Colosimo, S., Zang, E., and Weisburger, J.H. (1994) Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male F344 rat. Xenobiotica 24, 119-127.
151. Bu-Abbas, A., Clifford, M. N., Ioannides, C., and Walker, R. (1995) Stimulation of rat hepatic UDP-glucuronosyl transferase activity following treatment with green tea. Food Chem. Toxicol. 33, 27-30.
152. Emi, Y., Ikushiro, S., and Kato, Y. (2007) Thyroxine-metabolizing rat uridine diphosphate-glucuronosyltransferase 1A7 is regulated by thyroid hormone receptor. Endocrinology 148, 6124-6133.
153. Kohn, M. C. (2000) Effects of TCDD on thyroid hormone homeostasis in the rat. Drug Chem. Toxicol. 23, 259-277.
154. Wade, M. G., Parent, S., Finnson, K. W., Foster, W., Younglai, E., McMahon, A., Cyr, D. G., and Hughes, C. (2002) Thyroid toxicity due to subchronic exposure to a complex mixture of 16 organochlorines, lead, and cadmium. Toxicol. Sci. 67, 207-218.
155. Pesatori, A. C., Consonni, D., Bachetti, S., Zocchetti, C., Bonzini, M., Baccarelli, A., and Bertazzi, P. A. (2003) Short- and long-term morbidity and mortality in the population exposed to dioxin after the "Seveso accident." Ind. Health 41, 127-138.
156. Johnson, E., Shorter, C., Bestervelt, L., Patterson, D., Needham, L., Piper,W., Lucier, G., and Nolan, C. (2001) Serum hormone levels in humans with low serum concentrations of 2,3,7,8-TCDD. Toxicol. Ind. Health 17, 105-112.
157. Safe, S. and McDougal, A. (2002) Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Int. J. Oncol. 20, 1123-1128.
158. Safe, S. H. and Zacharewski, T. (1997) Organochlorine exposure and risk for breast cancer. Prog. Clin. Biol. Res. 396, 133-145.
159. Lu, F., Zahid, M., Saeed, M., Cavalieri, E. L., and Rogan, E. G. (2007) Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J. Steroid Biochem. Mol. Biol. 105, 150-158.
160. Tanaka, J., Yonemoto, J., Zaha, H., Kiyama, R., and Sone, H. (2007) Estrogen-responsive genes newly found to be modified by TCDD exposure in human cell lines and mouse systems. Mol. Cell Endocrinol. 272, 38-49.
161. Maliakal, P. P., Coville, P. F., and Wanwimolruk, S. (2001) Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats. J. Pharm. Pharmacol. 53, 569-577.
162. Morel, F., Fardel, O., Meyer, D. J., Langouet, S., Gilmore, K. S., Meunier, B., Tu, C. P., Kensler, T.W., Ketterer, B., and Guillouzo, A. (1993) Preferential increase of glutathione S-transferase class alpha transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolethiones. Cancer Res. 53, 231-234.
163. Schrenk, D., Stuven, T., Gohl, G., Viebahn, R., and Bock, K. W. (1995) Induction of CYP1A and glutathione S-transferase activities by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatocyte cultures. Carcinogenesis 16, 943-946.
164. Gao, X., Dinkova-Kostova, A. T., and Talalay, P. (2001) Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl Acad. Sci. USA 98, 15221-15226.
165. Ramos-Gomez, M., Kwak, M. K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., and Kensler, T.W. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl Acad. Sci. USA 98, 3410-3415.
166. Thimmulappa, R. K., Mai, K. H., Srisuma, S., Kensler, T.W., Yamamoto, M., and Biswal, S. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62, 5196-5203.
167. Nguyen, T., Sherratt, P. J., and Pickett, C. B. (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 43, 233-260.
168. Ma, Q., Kinneer, K., Bi, Y., Chan, J. Y., and Kan, Y. W. (2004) Induction of murine NAD(P)H:quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzo-p-dioxin requires the CNC (cap 'n' collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduction. Biochem. J. 377, 205-213.
169. Kohle, C. and Bock, K. W. (2006) Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals in relation to chemoprevention. Biochem. Pharmacol. 72, 795-805.
170. Miao, W., Hu, L., Scrivens, P. J., and Batist, G. (2005) Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drugmetabolizing enzymes. J. Biol. Chem. 280, 20340-20348.
171. Radjendirane, V. and Jaiswal, A. K. (1999) Antioxidant response element-mediated 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induction of human NAD(P)H:quinone oxidoreductase 1 gene expression. Biochem. Pharmacol. 58, 1649-1655.
172. Ross, D. (2004) Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 36, 639-654.
173. Friling, R. S., Bensimon, A., Tichauer, Y., and Daniel, V. (1990) Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc. Natl Acad. Sci. USA 87, 6258-6262.
174. Rushmore, T. H., Morton, M. R., and Pickett, C. B. (1991) The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 266, 11632-11639.
175. Wasserman, W. W. and Fahl, W. E. (1997) Functional antioxidant responsive elements. Proc. Natl Acad. Sci. USA 94, 5361-5366.
176. Itoh, K.,Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., and Yamamoto, M. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13, 76-86.
177. Kang, M. I., Kobayashi, A., Wakabayashi, N., Kim, S. G., and Yamamoto, M. (2004) Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc. Natl Acad. Sci. USA 101, 2046-2051.
178. Venugopal, R. and Jaiswal, A. K. (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl Acad. Sci. USA 93, 14960-14965.
179. Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236, 313-322.
180. Jeyapaul, J. and Jaiswal, A. K. (2000) Nrf2 and c-Jun regulation of antioxidant response element (ARE)-mediated expression and induction of gamma-glutamylcysteine synthetase heavy subunit gene. Biochem. Pharmacol. 59, 1433-1439.
181. Zhu, M. and Fahl, W. E. (2001) Functional characterization of transcription regulators that interact with the electrophile response element. Biochem. Biophys. Res. Commun. 289, 212-219.
182. Chan, J. Y. and Kwong, M. (2000) Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim. Biophys. Acta 1517, 19-26.
183. Chanas, S. A., Jiang, Q., McMahon, M., McWalter, G. K., McLellan, L. I., Elcombe, C. R., Henderson, C. J.,Wolf, C. R., Moffat, G. J., Itoh, K., et al. (2002) Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem. J. 365, 405-416.
184. McMahon, M., Itoh, K., Yamamoto, M., Chanas, S. A., Henderson, C. J., McLellan, L. I.,Wolf, C. R.,Cavin,C., and Hayes, J.D. (2001) TheCap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 61, 3299-3307.
185. Bingham, S. and Riboli, E. (2004) Diet and cancer-the European prospective investigation into cancer and nutrition. Nat. Rev. Cancer 4, 206-215.
186. Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R., et al. (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35, 238-245.
187. Okawa, H.,Motohashi, H., Kobayashi, A., Aburatani, H., Kensler, T.W., and Yamamoto, M. (2006) Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun. 339, 79-88.
188. Uchida, K. (2003) 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42, 318-343.
189. Enomoto, A., Itoh, K., Nagayoshi, E., Haruta, J., Kimura, T., O'Connor, T., Harada, T., and Yamamoto, M. (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59, 169-177.
190. Chan, K. and Kan, Y. W. (1999) Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl Acad. Sci. USA 96, 12731-12736.
191. Munzel, P. A., Schmohl, S., Buckler, F., Jaehrling, J., Raschko, F. T., Kohle, C., and Bock, K.W. (2003) Contribution of the Ah receptor to the phenolic antioxidant-mediated expression of human and rat UDP-glucuronosyltransferase UGT1A6 in Caco-2 and rat hepatoma 5L cells. Biochem. Pharmacol. 66, 841-847.
192. Chan, K., Han, X. D., and Kan, Y. W. (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl Acad. Sci. USA 98, 4611-4616.
193. Shelby, M. K. and Klaassen, C. D. (2006) Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways. Drug Metab. Dispos. 34, 1772-1778.
194. Yueh, M. F. and Tukey, R. H. (2007) Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. J. Biol. Chem. 282, 8749-8758.
195. Ma, Q., Battelli, L., and Hubbs, A. F. (2006) Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am. J. Pathol. 168, 1960-1974.
196. Corton, J. C., Anderson, S. P., and Stauber, A. (2000) Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40, 491-518.
197. Lemberger, T., Desvergne, B., and Wahli, W. (1996) Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 12, 335-363.
198. Kota, B. P., Huang, T. H., and Roufogalis, B. D. (2005) An overview on biological mechanisms of PPARs. Pharmacol. Res. 51, 85-94.
199. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366.
200. Gearing, K. L., Gottlicher, M., Teboul, M., Widmark, E., and Gustafsson, J. A. (1993) Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl Acad. Sci. USA 90, 1440-1444.
201. Barbier, O., Fontaine, C., Fruchart, J. C., and Staels, B. (2004) Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes. Trends Endocrinol. Metab. 15, 324-330.
202. Barbier, O., Villeneuve, L., Bocher, V., Fontaine, C., Torra, I. P., Duhem, C., Kosykh, V., Fruchart, J. C., Guillemette, C., and Staels, B. (2003) The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J. Biol. Chem. 278, 13975-13983.
203. Trottier, J., Verreault, M., Grepper, S., Monté, D., Bélanger, J., Kaeding, J., Caron, P., Inaba, T., and Barbier, O. (2006) Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic in the liver. Hepatology 44, 1158-1170.
204. Senekeo-Effenberger, K., Chen, S., Brace-Sinnokrak, E., Bonzo, J. A., Yueh, M. F., Argikar, U., Kaeding, J., Trottier, J., Remmel, R. P., Ritter, J. K., et al. (2007) Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab. Dispos. 35, 419-427.
205. Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J. C., Glineur, C., and Staels, B. (2002) Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22, 717-726.
206. Turgeon, D.,Chouinard, S., Belanger, P., Picard, S., Labbe, J. F., Borgeat, P., andBelanger, A. (2003) Glucuronidation of arachidonic and linoleic acid metabolites by human UDPglucuronosyltransferases. J. Lipid Res. 44, 1182-1191.
207. Barbier, O., Duran-Sandoval, D., Pineda-Torra, I., Kosykh, V., Fruchart, J. C., and Staels, B. (2003) Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278, 32852-32860.
208. Chapman, M. J. (2003) Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171, 1-13.
209. Ogilvie,B.W., Zhang, D., Li,W.,Rodrigues, A. D.,Gipson, A. E.,Holsapple, J., Toren, P., and Parkinson, A. (2006) Glucuronidation converts gemfibrozil to a potent, metabolismdependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 34, 191-197.
210. Sakai, M., Matsushima-Hibiya, Y., Nishizawa, M., and Nishi, S. (1995) Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between Jun and peroxisome proliferator-activated receptor alpha. Cancer Res. 55, 5370-5376.
211. Fan, L. Q., You, L., Brown-Borg, H., Brown, S., Edwards, R. J., and Corton, J. C. (2004) Regulation of phase I and phase II steroidmetabolism enzymes by PPAR alpha activators. Toxicology 204, 109-121.
212. Jiang, Y. J., Kim, P., Elias, P. M., and Feingold, K. R. (2005) LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes. J. Lipid Res. 46, 2657-2666.
213. Dixit, S. G., Tirona, R. G., and Kim, R. B. (2005) Beyond CAR and PXR. Curr. Drug Metab. 6, 385-397.
214. Sporn, M. B., Suh, N., and Mangelsdorf, D. J. (2001) Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol. Med. 7, 395-400.
215. Barbier, O., Girard, H., Inoue, Y., Duez, H., Villeneuve, L., Kamiya, A., Fruchart, J. C., Guillemette, C., Gonzalez, F. J., and Staels, B. (2005) Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol. Pharmacol. 67, 241-249.
216. Ericsson, H., Hamren, B., Bergstrand, S., Elebring, M., Fryklund, L., Heijer, M., and Ohman, K. P. (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dualacting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos. 32, 923-929.
217. Paumi, C.M., Smitherman, P. K., Townsend, A. J., and Morrow, C. S. (2004) Glutathione S-transferases (GSTs) inhibit transcriptional activation by the peroxisomal proliferatoractivated receptor gamma (PPAR gamma) ligand, 15-deoxy-delta 12,14prostaglandin J2 (15-d-PGJ2). Biochemistry 43, 2345-2352.
218. Kliewer, S. A. and Willson, T. M. (2002) Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res. 43, 359-364.
219. Barbier, O., Torra, I. P., Sirvent, A., Claudel, T., Blanquart, C., Duran-Sandoval, D., Kuipers, F., Kosykh, V., Fruchart, J. C., and Staels, B. (2003) FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124, 1926-1940.
220. Lu, Y., Heydel, J. M., Li, X., Bratton, S., Lindblom, T., and Radominska-Pandya, A. (2005) Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element. Drug Metab. Dispos. 33, 937-946.
221. Kitada, H., Miyata, M., Nakamura, T., Tozawa, A., Honma, W., Shimada, M., Nagata, K., Sinal, C. J., Guo, G. L., Gonzalez, F. J., et al. (2003) Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. J. Biol. Chem. 278, 17838-17844.
222. Uppal, H., Saini, S. P., Moschetta, A., Mu, Y., Zhou, J., Gong, H., Zhai, Y., Ren, S., Michalopoulos, G. K., Mangelsdorf, D. J., et al. (2007) Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45, 422-432.
223. Verreault, M., Senekeo-Effenberger, K., Trottier, J., Bonzo, J. A., Bélanger, J., Kaeding, J., Staels, B., Caron, P., Tukey, R. H., and Barbier, O. (2006) The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. Hepatology 44, 368-378.
224. Gong, H., Guo, P., Zhai, Y., Zhou, J., Uppal, H., Jarzynka, M. J., Song, W. C., Cheng, S. Y., and Xie, W. (2007) Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol. Endocrinol. 21, 1781-1790.
225. Kaeding, J.,Bouchaert, E.,Bélanger, J.,Caron, P.,Chouinard, S.,Verreault, M., Larouche, O., Pelletier, G., Staels, B., Bélanger, A., et al. (2008) Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochem. J. 410, 245-253.
226. Frain, M., Swart, G., Monaci, P., Nicosia, A., Stampfli, S., Frank, R., and Cortese, R. (1989) The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 59, 145-157.
227. Bartkowski, S., Zapp, D., Weber, H., Eberle, G., Zoidl, C., Senkel, S., Klein-Hitpass, L., and Ryffel, G. U. (1993) Developmental regulation and tissue distribution of the liver transcription factor LFB1 (HNF1) in Xenopus laevis. Mol. Cell Biol. 13, 421-431.
228. Yamagata, K., Furuta, H., Oda, N., Kaisaki, P. J., Menzel, S., Cox, N. J., Fajans, S. S., Signorini, S., Stoffel,M., andBell, G. I. (1996) Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 384, 458-460.
229. Yamagata, K., Oda, N., Kaisaki, P. J., Menzel, S., Furuta, H., Vaxillaire, M., Southam, L., Cox, R. D., Lathrop, G. M., Boriraj, V. V., et al. (1996) Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455-458.
230. Kanou, M., Usui, T., Ueyama, H., Sato, H., Ohkubo, I., and Mizutani, T. (2004) Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone. Mol. Biol. Rep. 31, 151-158.
231. Auyeung, D. J.,Kessler, F.K., and Ritter, J.K. (2001) An alternative promoter contributes to tissue- and inducer-specific expression of the rat UDP-glucuronosyltransferase 1A6 gene. Toxicol. Appl. Pharmacol. 174, 60-68.
232. Gregory, P. A., Lewinsky, R. H., Gardner-Stephen, D. A., and Mackenzie, P. I. (2004) Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol. Appl. Pharmacol. 199, 354-363.
233. Metz, R. P., Auyeung, D. J., Kessler, F. K., and Ritter, J. K. (2000) Involvement of hepatocyte nuclear factor 1 in the regulation of the UDP-glucuronosyltransferase 1A7 (UGT1A7) gene in rat hepatocytes. Mol. Pharmacol. 58, 319-327.
234. Hansen, A. J., Lee, Y. H., Gonzalez, F. J., and Mackenzie, P. I. (1997) HNF1 alpha activates the rat UDP glucuronosyltransferase UGT2B1 gene promoter. DNA Cell Biol. 16, 207-214.
235. Hansen, A. J., Lee, Y. H., Sterneck, E., Gonzalez, F. J., and Mackenzie, P. I. (1998) C/EBPalpha is a regulator of the UDP glucuronosyltransferase UGT2B1 gene. Mol. Pharmacol. 53, 1027-1033.
236. Ishii, Y., Hansen, A. J., and Mackenzie, P. I. (2000) Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol. Pharmacol. 57, 940-947.
237. Chen, W. S., Manova, K., Weinstein, D. C., Duncan, S. A., Plump, A. S., Prezioso, V. R., Bachvarova, R. F., and Darnell, J. E., Jr. (1994) Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev. 8, 2466-2477.
238. Odom, D. T., Zizlsperger, N., Gordon, D. B., Bell, G. W., Rinaldi, N. J., Murray, H. L., Volkert, T. L., Schreiber, J., Rolfe, P. A., Gifford, D. K., et al. (2004) Control of pancreas and liver gene expression by HNF transcription factors. Science 303, 1378-1381.
239. Kamiyama, Y., Matsubara, T., Yoshinari, K., Nagata, K., Kamimura, H., and Yamazoe, Y. (2007) Role of human hepatocyte nuclear factor 4alpha in the expression of drugmetabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab. Pharmacokinet. 22, 287-298.
240. Kamiya, A., Inoue, Y., and Gonzalez, F. J. (2003) Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology 37, 1375-1384.
241. Li, J., Ning, G., and Duncan, S. A. (2000) Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. Genes Dev. 14, 464-474.
242. Bhalla, S., Ozalp, C., Fang, S., Xiang, L., and Kemper, J. K. (2004) Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279, 45139-45147.
243. Li, T. and Chiang, J. Y. (2005) Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G74-G84.
244. Miao, J., Fang, S., Bae, Y., and Kemper, J. K. (2006) Functional inhibitory crosstalk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. J. Biol. Chem. 281, 14537-14546.
245. Fang, H. L., Strom, S. C., Ellis, E., Duanmu, Z., Fu, J., Duniec-Dmuchowski, Z., Falany, C. N., Falany, J. L., Kocarek, T. A., and Runge-Morris, M. (2007) Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J. Pharmacol. Exp. Ther. 323, 586-598.
246. Liu, L. and Klaassen, C. D. (1996) Regulation of hepatic sulfotransferases by steroidal chemicals in rats. Drug Metab. Dispos. 24, 854-858.
247. Runge-Morris, M., Rose, K., and Kocarek, T. A. (1996) Regulation of rat hepatic sulfotransferase gene expression by glucocorticoid hormones. Drug Metab. Dispos. 24, 1095-1101.
248. Runge-Morris, M.,Wu, W., and Kocarek, T. A. (1999) Regulation of rat hepatic hydroxysteroid sulfotransferase (SULT2-40/41) gene expression by glucocorticoids: evidence for a dual mechanism of transcriptional control. Mol. Pharmacol. 56, 1198-1206.
249. Duanmu, Z., Kocarek, T. A., and Runge-Morris, M. (2001) Transcriptional regulation of rat hepatic aryl sulfotransferase (SULT1A1) gene expression by glucocorticoids. Drug Metab. Dispos. 29, 1130-1135.
250. Chouinard, S., Pelletier, G., Bélanger, A., and Barbier, O. (2006) Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 147, 5431-5442.
251. Chouinard, S., Barbier, O., and Bélanger, A. (2007) UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J. Biol. Chem. 282, 33466-33474.
252. Harrington,W. R., Sengupta, S., and Katzenellenbogen, B. S. (2006) Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology 147, 3843-3850.
253. Starlard-Davenport, A., Lyn-Cook, B., and Radominska-Pandya, A. (2008) Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene. Steroids 73, 139-147.
254. Adams, J. B.,Vrahimis, R., and Phillips, N. (1992) Regulation of estrogen sulfotransferase by estrogen in MCF-7 human mammary cancer cells. Breast Cancer Res. Treat. 22, 157-161.
255. Seely, J., Amigh, K. S., Suzuki, T., Mayhew, B., Sasano, H., Giguere, V., Laganiere, J., Carr, B. R., and Rainey, W. E. (2005) Transcriptional regulation of dehydroepiandrosterone sulfotransferase (SULT2A1) by estrogen-related receptor alpha. Endocrinology 146, 3605-3613.
256. Labrie, F., Luu-The, V., Bélanger, A., Lin, S. X., Simard, J., Pelletier, G., and Labrie, C. (2005) Is dehydroepiandrosterone a hormone? J. Endocrinol. 187, 169-196.
257. Lu, C. and Li, A. P. (2001) Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem. Biol. Interact. 134, 271-281.